Curian Capital Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Curian Capital reduced its stake in Eli Lilly and Co by 63.72% during the most recent quarter end. The investment management company now holds a total of 64,037 shares of Eli Lilly and Co which is valued at $5,101,187 after selling 112,474 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Jul 6, 2016.Eli Lilly and Co makes up approximately 0.36% of Curian Capital’s portfolio.

Other Hedge Funds, Including , Laurel Wealth Advisors reduced its stake in LLY by selling 653 shares or 10.64% in the most recent quarter. The Hedge Fund company now holds 5,485 shares of LLY which is valued at $436,935. Eli Lilly and Co makes up approx 0.21% of Laurel Wealth Advisors’s portfolio.First Financial Bank N.a. – Trust Division reduced its stake in LLY by selling 400 shares or 2.48% in the most recent quarter. The Hedge Fund company now holds 15,745 shares of LLY which is valued at $1,253,932. Eli Lilly and Co makes up approx 0.24% of First Financial Bank N.a. – Trust Division’s portfolio. New England Research Management added LLY to its portfolio by purchasing 7,400 company shares during the most recent quarter which is valued at $589,336. Eli Lilly and Co makes up approx 0.51% of New England Research Management’s portfolio.Cullinan Associates Inc reduced its stake in LLY by selling 300 shares or 0.93% in the most recent quarter. The Hedge Fund company now holds 32,067 shares of LLY which is valued at $2,531,690. Eli Lilly and Co makes up approx 0.21% of Cullinan Associates Inc’s portfolio.

Eli Lilly and Co closed down -0.52 points or -0.65% at $79.14 with 34,61,430 shares getting traded on Monday. Post opening the session at $79.54, the shares hit an intraday low of $78.95 and an intraday high of $79.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.